Evidence question

PubMed sourcedAbstract-based analysisUpdated Sep 2026Human reviewedUpdated Aug 2026

Evidence / Menopause & Women's Health

CoverageMenopause & Women's Health

Does menopause cause weight gain and can hormone therapy help?

Reviewed by Neal Rouzier, MD, Preventive Medicine · Aug 2026

Updated Aug 2026·10 studies analyzed·2 core studies·Applies to: perimenopausal and early postmenopausal women

Bottom line

Menopause is associated with central adiposity and lean mass loss independent of aging alone. Hormone therapy is not a weight-loss treatment but may attenuate some menopause-related body composition shifts in selected women.[1–6]

Evidence confidence

Evidence Confidence

Moderate
LimitedModerateHigh

Relevant evidence exists, but study designs, populations, or conclusions differ enough to keep certainty moderate.

Key uncertainty. Magnitude of HRT effect on weight is modest and inconsistent.

Ask RAGMD

Get the live evidence synthesis

10 complimentary queries. Full clinical intelligence — PubMed citations, conflict analysis, Evidence Confidence — with 7-day free trial.

Ask this questionStart free trialWhy physicians use RAGMD

Also asked

Does HRT cause weight gain in menopause?▼

Menopause shifts fat centrally and reduces lean mass. HRT is not a weight-loss drug; it may modestly blunt some body-composition changes when otherwise indicated.

Does HRT help with belly fat in menopause?▼

Estrogen-based HRT may reduce central fat accumulation after menopause compared to no treatment, but effect sizes are modest. HRT is not indicated for weight management alone.

Will I gain weight on hormone replacement therapy?▼

Clinical trial data do not show significant weight gain attributable to HRT when used at standard doses. Some women notice fluid retention early in treatment, which is different from fat gain.

Menopause muscle loss estrogen▼

Estrogen decline after menopause contributes to loss of lean mass. HRT does not fully prevent sarcopenia; resistance exercise combined with adequate protein intake remains the most effective intervention.

Menopause weight gain HRT▼

Menopause is associated with central adiposity and lean mass loss independent of aging alone. Hormone therapy is not a weight-loss treatment but may attenuate some menopause-related body composition shifts in selected women.

Postmenopausal body composition▼

Menopause is associated with central adiposity and lean mass loss independent of aging alone. Hormone therapy is not a weight-loss treatment but may attenuate some menopause-related body composition shifts in selected women.

Body of evidence

Clinical Evidence Brief

RAGMD analyzed 10 relevant studies.

Overall finding

8 studies address vasomotor symptom associations, with weighted findings showing mixed findings. 2 studies address long-term cognitive decline / dementia, with weighted findings showing a negative association. 2 studies address venous thromboembolism, with weighted findings showing a positive association. 2 studies address breast cancer, with weighted findings showing a positive association. 4 randomized or systematic-review reports and 5 observational studies address treatment.

Evidence by outcome

Direction: ↑ Favors treatment / reassuring · ↓ Harm signal · ↔ No clear effect · ± Mixed · ↗ Observational link · ? Unclear

Mixed

Vasomotor symptom associations

moderate · 8 studies

8 studies address vasomotor symptom associations, with weighted findings showing mixed findings. This is a patient-reported / subjective outcome.

Patient-reported

Studies

PMID 42606770PMID 41307293PMID 29322164PMID 26838086PMID 38016166PMID 36749328PMID 40253593PMID 34513605
Negative link

Long-term cognitive decline / dementia

moderate · 2 studies

2 studies address long-term cognitive decline / dementia, with weighted findings showing a negative association. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 41307293PMID 34513605
Positive link

Venous thromboembolism

moderate · 2 studies

2 studies address venous thromboembolism, with weighted findings showing a positive association. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 41307293PMID 36749328
Positive link

Breast cancer

moderate · 2 studies

2 studies address breast cancer, with weighted findings showing a positive association. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 41307293PMID 36749328
Unclear

Mortality

moderate · 1 study

1 study addresses mortality, with weighted findings showing unclear findings. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 41307293
Unclear

Fertility / spermatogenesis

moderate · 1 study

1 study addresses fertility / spermatogenesis, with weighted findings showing unclear findings. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 41307293

Magnitude / clinical importance

Validated effect estimates in the analyzed set include RR 1.17; or 4. Statistical significance is not the same as clinical importance.

Where quantified, effects were often statistically detectable but small in absolute terms.

Agreement across studies

Most studies agree on vasomotor symptom associations (mixed findings), while long-term cognitive decline / dementia findings are a negative association and more consistent across domains.

Supports main conclusion: 5 · Neutral / mixed: 5 · Credible conflicting: 0

Study counts describe the landscape; RAGMD weights studies according to design, quality, and directness.

Conflicting findings

  • PURPOSE OF REVIEW: Perimenopause is a period of hormonal volatility associated with clinically relevant changes in metabolism and cardiometabolic risk.
  • Long-term follow-up of women using hormone therapy suggests that the risk profiles vary between combined hormone therapy and oestrogen-only therapy.
  • Brain fog, referring to menopause-related subjective cognitive difficulties, is common in midlife women.

Risks & harms

1 study reports safety-relevant findings. Design mix: Narrative review. Rare-event inference should not rest on underpowered trials alone.

Who this applies to

Most studies included perimenopausal and early postmenopausal women.

What remains uncertain

  • Magnitude of HRT effect on weight is modest and inconsistent.
  • Magnitude of HRT effect on weight is modest and inconsistent.
  • Typical subjective cognitive complaints are not established as equivalent to dementia.

Clinical takeaway

Counsel that menopause-related central adiposity responds to lifestyle intervention first. Hormone therapy may attenuate some body-composition shifts but is not a weight-loss strategy and should be prescribed for appropriate indications.

Mixed

Vasomotor symptom associations?

Mixed findings

moderate[42606770 · 41307293 · 29322164 · 26838086 · 38016166 · 36749328 · 40253593 · 34513605]

Negative link

Long-term cognitive decline / dementia?

A negative association

moderate[41307293 · 34513605]

Positive link

Venous thromboembolism?

A positive association

moderate[41307293 · 36749328]

Positive link

Breast cancer?

A positive association

moderate[41307293 · 36749328]

Unclear

Mortality?

Unclear findings

moderate[41307293]

Unclear

Fertility / spermatogenesis?

Unclear findings

moderate[41307293]

Unclear

Fractures?

Unclear findings

moderate[41307293]

Mixed

Mood-related cognitive symptoms?

Mixed findings

moderate[29322164]

4 randomized or systematic-review reports and 5 observational studies address treatment. Weighted treatment findings show mixed findings.

4 RCT / systematic review · 5 observational

Large randomized trials strongly influence the conclusion

2 landmark studies with randomized or systematic-review designs strongly inform this conclusion.

Supporting studies provide additional context

8 supporting studies add context beyond the core evidence base.

Regimen & duration

Differences in hormone type, dose, duration, and patient population affect how results should be interpreted.

Long-term uncertainty

Study quality or consistency across available evidence limits certainty.

10 analyzed studies

Strongest evidence

Current nutrition reports2026

Landmark studyPMID 42606770

Metabolic Changes of Perimenopause and Nutritional Advice.

PURPOSE OF REVIEW: Perimenopause is a period of hormonal volatility associated with clinically relevant changes in metabolism and cardiometabolic risk. In addition to vasomotor symptoms, sleep disruption, and changes in body composition, the transition from the late reproductive years to early postmenopause is characterized by physiologic alterations that may precede formal diagnostic thresholds for metabolic syndrome.

Review
Evidence
Relevance
The Cochrane database of systematic reviews2025

Landmark studyPMID 41307293

Long-term hormone therapy for perimenopausal and postmenopausal women.

Long-term follow-up of women using hormone therapy suggests that the risk profiles vary between combined hormone therapy and oestrogen-only therapy. Oestrogen-only hormone therapy probably makes little to no difference to coronary events, and probably increases the risk of stroke and gallbladder disease.

Systematic review
Evidence
Relevance

Supporting literature

Efficacy of Transdermal Estradiol and Micronized Progesterone in the Prevention of Depressive Symptoms in the Menopause Transition: A Randomized Clinical Trial.

Hormone Therapy for Relieving Postmenopausal Vasomotor Symptoms: A Systematic Review.

Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopause.

+5 more

More in this focus area

Related evidence analyses

Other structured clinical questions in Menopause & Women's Health.

Does hormone replacement therapy increase breast cancer risk?

Combined estrogen-progestin therapy is associated with a small increased breast cancer risk in WHI and observational data. Estrogen-alone in hysterectomized women showed lower risk in WHI, but interpretation depends on regimen, duration, and individual risk factors.

10 linked studies

Does hormone replacement therapy reduce cardiovascular risk in early menopause?

The timing hypothesis suggests earlier initiation may differ from late initiation, where WHI showed harm for combined therapy. Current guidelines emphasize individualized risk assessment rather than routine cardioprotection.

14 linked studies

Does hormone replacement therapy increase venous thromboembolism risk?

Oral estrogen increases venous thromboembolism risk compared with no therapy. Transdermal estrogen appears to carry lower thrombotic risk in observational studies and is often preferred in women at elevated VTE risk.

14 linked studies

Is there a critical timing window for cardiovascular benefit from HRT?

The critical-window concept proposes that starting HRT closer to menopause may yield different cardiovascular effects than starting later. WHI subgroup analyses inform but do not prove this hypothesis for routine practice.

14 linked studies

Go deeper on Menopause & Women's Health

Full evidence synthesis, study comparisons, conflicting evidence, and expert commentary are available with RAGMD. Ask follow-up questions, explore related topics, and see how the evidence has evolved.

Ask RAGMDExplore Menopause & Women's HealthView pricing